Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ZomedicaZOMDF +1.50% Earnings per Share (Diluted) is $-0.01 as of Jun. 2026. The stock has 2 warning signs investors should review. Among 658 Medical Devices & Instruments companies, Zomedica ranks worse than 73.71% on this metric.
Zomedica's EPS (Basic) for the
three
months ended in Jun. 2026 was $0.00.
Its EPS (Basic) for the trailing twelve months (TTM) ended in Jun. 2026 was $-0.01.
Zomedica's EPS without NRI for the
three
months ended in Jun. 2026 was $0.00.
Its EPS without NRI for the trailing twelve months (TTM) ended in Jun. 2026 was $-0.01.
During the past 3 years, the average EPS without NRIGrowth Rate was -10.60% per year.
During the past 5 years, the average EPS without NRIGrowth Rate was 12.10% per year.
During the past 10 years, the average EPS without NRIGrowth Rate was 5.30% per year.
During the past 13 years, Zomedica's highest 3-Year average EPS without NRI Growth Rate was 55.30% per year. The lowest was -123.70% per year. And the median was 12.90% per year.
Zomedica (OTCPK:ZOMDF) Earnings per Share (Diluted) Explanation
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.
Be Aware
Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.
If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.
Zomedica Earnings per Share (Diluted) Related Terms
Zomedica Earnings per Share (Diluted) Historical Data
* Premium members only.
The historical data trend for Zomedica's Earnings per Share (Diluted) can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ZOMDF vs SERA, HYPR, OM: Earnings per Share (Diluted) Comparison
For the Medical Devices subindustry, Zomedica's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Zomedica PE Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Zomedica's PE Ratio distribution charts can be found below:
* The bar in red indicates where Zomedica's PE Ratio falls into.
Earnings Per Share (EPS) is the amount of earnings per outstanding share of the company's stock. In calculating earnings per share, the dividends of preferred stocks need to subtracted from the total net income first.
Zomedica's Earnings Per Share (Diluted) for the fiscal year that ended in Dec. 2025 is calculated as
Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.01
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Companies also reported diluted shares in their financial reports. Diluted shares include the shares of convertibles or warrants outstanding.
What does a Earnings per Share (Diluted) of $-0.01 mean?
Zomedica (ZOMDF) has a Earnings per Share (Diluted) of $-0.01 as of Jun. 2026. Diluted EPS equals net earnings divided by average shares outstanding, including dilutive securities. View historical data on Zomedica and its competitors. According to the industry distribution chart, Zomedica ranks #485 out of 658 companies in the Medical Devices & Instruments industry, placing it in the top 73.7%.
Is Zomedica's Earnings per Share (Diluted) too high?
Zomedica's current Earnings per Share (Diluted) is $-0.01. Based on the distribution chart, Zomedica ranks #485 out of 658 companies in the Medical Devices & Instruments industry, which is below the industry midpoint.
How does Zomedica's Earnings per Share (Diluted) compare to SERA and HYPR?
According to the Medical Devices & Instruments industry distribution chart, Zomedica ranks #485 out of 658 companies for Earnings per Share (Diluted). This places Zomedica in the lower half of its industry. The industry median Earnings per Share (Diluted) is 8.05. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Earnings per Share (Diluted) for a Medical Devices & Instruments company?
The median Earnings per Share (Diluted) among Medical Devices & Instruments companies is 8.05, based on 658 companies in the industry. Companies in the top quartile (top 25%) have a Earnings per Share (Diluted) significantly above this median, while those in the bottom quartile fall well below. However, Earnings per Share (Diluted) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Earnings per Share (Diluted) mean?
A high Earnings per Share (Diluted) can signal that a stock is expensive relative to its fundamentals. Diluted EPS equals net earnings divided by average shares outstanding, including dilutive securities. View historical data on Zomedica and its competitors. For the Medical Devices & Instruments industry, the median Earnings per Share (Diluted) is 8.05 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Zomedica's current Earnings per Share (Diluted) is $-0.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zomedica stock overvalued right now?
Based on GuruFocus' analysis, Zomedica (ZOMDF) is currently considered Possible Value Trap. The stock's GF Value™ is $0.18, compared to a current price of $0.08 — trading 53% below its estimated fair value. The current Earnings per Share (Diluted) is $-0.01. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Earnings per Share (Diluted) calculated?
Earnings per Share (Diluted) is calculated from a company's financial statements. For Zomedica (ZOMDF), the current Earnings per Share (Diluted) is $-0.01 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Zomedica Corp is a veterinary health company creating products for companion animals (canine, feline and equine) by focusing on the unmet needs of clinical veterinarians. The company's product portfolio includes diagnostics and therapeutics that emphasize patient health and practice health. The company is focused on the final development and commercialization of its TRUFORMA platform, which detects thyroid disorders in dogs & cats and adrenal disorders in dogs. Its segments consist of Diagnostics, Therapeutic Devices, and Development Services. It earns the majority of revenue from the therapeutics segment, which consists of Assisi, PulseVet, and VETIGEL products.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ZOMDF has been successfully added to your 
